Compare VLRS & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLRS | LENZ |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.2M | 106.8M |
| IPO Year | 2013 | 2021 |
| Metric | VLRS | LENZ |
|---|---|---|
| Price | $8.57 | $4.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | $9.05 | ★ $14.83 |
| AVG Volume (30 Days) | 960.2K | ★ 1.2M |
| Earning Date | 10-26-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | $27.86 | N/A |
| Revenue Next Year | $7.37 | $125.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.46 | $2.80 |
| 52 Week High | $10.80 | $32.13 |
| Indicator | VLRS | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 83.13 | 60.49 |
| Support Level | $6.95 | $3.60 |
| Resistance Level | $9.74 | $6.11 |
| Average True Range (ATR) | 0.37 | 0.37 |
| MACD | 0.30 | 0.14 |
| Stochastic Oscillator | 99.97 | 86.62 |
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.